Marizomib (MRZ) with bevacizumab (BEV) in who grade iv malignant glioma (G4 mg): Full enrollment results from the phase 1, multicenter, open-label study

Authors
Category Primary study
JournalNeuro-Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 2482a68d3a114ea64028ba222c37e8499bea6b36
First added on: Feb 08, 2025